Stoke Therapeutics, Inc. (STOK) Financial Statements (2026 and earlier)

Company Profile

Business Address 45 WIGGINS AVENUE
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments284,670216,899201,394229,595219,810287,308
Cash and cash equivalent84,220127,983191,442113,556144,895287,308
Short-term investments200,45088,9169,952116,03974,915 
Restricted cash and investments 49475    
Receivables7,905700645881326
Prepaid expense8,73611,11711,32010,932  
Other current assets3,8953,9652,5612,955  
Other undisclosed current assets     9,2766,616
Total current assets:305,700232,756215,339244,070229,218293,930
Noncurrent Assets
Operating lease, right-of-use asset3,1014,3456,6114,7534,9391,115
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization3,1463,9095,8236,6754,1392,675
Long-term investments and receivables106,26029,824    
Long-term investments106,26029,824    
Restricted cash and investments227721569569569205
Total noncurrent assets:112,73438,79913,00311,9979,6473,995
TOTAL ASSETS:418,434271,555228,342256,067238,865297,925
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,87911,2927,9577,0458,2916,293
Employee-related liabilities✕✕✕✕✕5,3834,123
Accounts payable4,9392,4981,6957662,3851,495
Accrued liabilities14,9408,7946,2626,279523675
Deferred revenue11,90118,99115,30914,880  
Other liabilities1,0607538575095401,443
Other undisclosed current liabilities25,0359,0206,6968,9608,3083,689
Total current liabilities:57,87540,05630,81931,39417,13911,425
Noncurrent Liabilities
Long-term debt and lease obligation:     3,53280
Liabilities, other than long-term debt8,1022,47837,95839,824  
Deferred revenue6,961 33,07436,856  
Other liabilities1,1412,4784,8842,968  
Operating lease, liability     3,53280
Other undisclosed noncurrent liabilities     (3,115)262
Total noncurrent liabilities:8,1022,47837,95839,8243,949422
Total liabilities:65,97742,53468,77771,21821,08811,847
Equity
Equity, attributable to parent352,457229,021159,565184,849217,777286,078
Common stock555444
Additional paid in capital849,624719,997561,433483,170414,024396,352
Accumulated other comprehensive income (loss)543(151)(24)(1,175)(168) 
Accumulated deficit(497,715)(490,830)(401,849)(297,150)(196,083)(110,278)
Total equity:352,457229,021159,565184,849217,777286,078
TOTAL LIABILITIES AND EQUITY:418,434271,555228,342256,067238,865297,925

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues184,42036,5558,78012,405  
Gross profit:184,42036,5558,78012,405  
Operating expenses(205,010)(137,927)(123,553)(116,761)(86,065)(53,044)
Operating loss:(20,590)(101,372)(114,773)(104,356)(86,065)(53,044)
Nonoperating income13,70512,39110,0743,289260801
Investment income, nonoperating      744
Other nonoperating income (expense)(51)(247)16616714057
Loss from continuing operations before income taxes:(6,885)(88,981)(104,699)(101,067)(85,805)(52,243)
Income tax benefit      
Loss from continuing operations:(6,885)(88,981)(104,699)(101,067)(85,805)(52,243)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(85,805)(52,243)
Net loss available to common stockholders, diluted:(6,885)(88,981)(104,699)(101,067)(85,805)(52,243)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(6,885)(88,981)(104,699)(101,067)(85,805)(52,243)
Other comprehensive income (loss)694(127)1,151(1,007)(168) 
Comprehensive loss, net of tax, attributable to parent:(6,191)(89,108)(103,548)(102,074)(85,973)(52,243)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: